Denosumab: an investigational drug for the management of postmenopausal osteoporosis.
Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for receptor activator of nuclear factor-kappaB ligand (RANKL), a cytokine member of the tumor necrosis factor family. RANKL, the principal mediator of osteoclastic bone resorption, plays a major role in the pathogenesis of postmenopausal osteoporosis and other skeletal disorders associated with bone loss. Denosumab inhibits the action of RANKL, thereby reducing the differentiation, activity, and survival of osteoclasts, and lowering the rate of bone resorption. Clinical trials have shown that denosumab increases bone mineral density (BMD) and reduces bone turnover in postmenopausal women with low BMD. Studies to evaluate the fracture risk benefit and long-term safety of denosumab in women with postmenopausal osteoporosis (PMO) are ongoing. Denosumab is a potential treatment for PMO and other skeletal disorders.
Lewiecki
E Michael
EM
New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USA.
J Bone Miner Res. 1992 Sep;7(9):1005-10
1414493
J Bone Miner Res. 1995 Feb;10(2):175-7
7754796
Am J Pathol. 2000 Aug;157(2):435-48
10934148
N Engl J Med. 2006 Feb 23;354(8):860-3
16495400
Osteoporos Int. 2003 Dec;14(12):965-8
14504697
J Bone Miner Res. 2005 Feb;20(2):177-84
15647810
Mayo Clin Proc. 2005 Feb;80(2):194-202
15704774
Biochem Biophys Res Commun. 2000 Aug 2;274(2):281-90
10913332
Endocrinology. 1991 Jul;129(1):421-8
2055197
Nature. 2003 May 15;423(6937):337-42
12748652
J Bone Miner Res. 2004 Jul;19(7):1059-66
15176987
J Immunol. 1999 Mar 1;162(5):2562-8
10072496
Bone. 2004 Apr;34(4):656-64
15050896
Nature. 1999 Jan 28;397(6717):315-23
9950424
Genes Dev. 1998 May 1;12(9):1260-8
9573043
J Exp Med. 1997 Dec 15;186(12):2075-80
9396779
Cell. 1997 Apr 18;89(2):309-19
9108485
Cancer. 2003 Feb 1;97(3 Suppl):887-92
12548591
JAMA. 2004 Jul 28;292(4):490-5
15280347
Cancer Res. 2003 Jan 15;63(2):287-9
12543775
J Clin Invest. 2003 Apr;111(8):1221-30
12697741
Endocrinology. 2001 Oct;142(10):4295-304
11564687
Arch Intern Med. 2003 Oct 13;163(18):2165-72
14557214
Lancet. 1999 Mar 13;353(9156):878-82
10093980
N Engl J Med. 2006 Feb 23;354(8):821-31
16495394
Arthritis Rheum. 2002 Mar;46(3):785-92
11920416
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1566-71
10677500
Bone. 2004 Jul;35(1):256-65
15207766
Osteoporos Int. 2007 Aug;18(8):1023-31
17308956
Am J Med. 1997 Aug 18;103(2A):12S-17S; discussion 17S-19S
9302893
Cell. 1998 Apr 17;93(2):165-76
9568710
J Clin Oncol. 2007 Oct 1;25(28):4431-7
17785705
Immunol Rev. 2005 Dec;208:207-27
16313351
Nature. 1999 Nov 18;402(6759):304-9
10580503
Maturitas. 2004 Jul 15;48(3):271-87
15207894
Bone. 2008 Aug;43(2):222-229
18539106
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3540-5
10097072
Gut. 2005 Jan;54(1):78-86
15591508
J Bone Miner Res. 2007 Mar;22(3):465-75
17144789
Bone. 2001 Feb;28(2):208-14
11182380
J Bone Miner Res. 2003 May;18(5):852-8
12733724
Osteoporos Int. 2000;11(5):373-80
10912837
J Immunol. 2007 Dec 1;179(11):7497-505
18025194
Osteoporos Int. 2005 Jun;16(6):581-9
15616758
J Cell Biol. 1999 May 3;145(3):527-38
10225954
JAMA. 2001 Feb 14;285(6):785-95
11176917
J Pharm Sci. 2004 Sep;93(9):2184-204
15295780
Endocrinology. 1999 Sep;140(9):4367-70
10465311
Arthritis Rheum. 2003 Jul;48(7):2042-51
12847699
J Mater Sci Mater Med. 2001 Jul;12(7):583-8
15348250
Circ Res. 2004 Nov 26;95(11):1046-57
15564564
J Clin Endocrinol Metab. 2004 Jul;89(7):3332-6
15240611
J Bone Miner Res. 2001 Feb;16(2):348-60
11204435
Osteoporos Int. 2004 Dec;15(12):1003-8
15167989
Osteoporos Int. 2004 Mar;15(3):175-9
14691617
J Bone Miner Res. 2007 Dec;22(12):1832-41
17708711
Arthritis Rheum. 2005 Oct;52(10):2960-7
16200575
Biochem Biophys Res Commun. 1998 May 8;246(1):199-204
9600092
Immunol Rev. 2005 Dec;208:19-29
16313338
Genes Dev. 1999 Sep 15;13(18):2412-24
10500098
J Pharm Sci. 2004 Nov;93(11):2645-68
15389672